That anxiety medication you took three years ago might still be affecting the trillions of bacteria living in your gut. A comprehensive study of over 2,500 people reveals that prescription drugs can leave persistent microbial “fingerprints” that remain detectable years after patients stop taking them, fundamentally challenging how researchers study the human microbiome.
The discovery emerged from an analysis of the Estonian Microbiome cohort, where researchers at the University of Tartu Institute of Genomics linked detailed prescription records with gut bacteria profiles from participants. What they found was striking: 89.8% of the 186 medications studied were associated with changes in gut microbiome composition, and nearly half showed long-term effects persisting years beyond treatment.
Anxiety Drugs Pack Antibiotic-Like Punch
Among the most surprising findings was the potent impact of benzodiazepines, commonly prescribed anti-anxiety medications including drugs like Xanax and Valium. These psychiatric medications produced microbiome disruptions comparable to broad-spectrum antibiotics, with effects detectable more than three years after discontinuation.
“Most microbiome studies only consider current medications, but our results show that past drug use can be just as important as it is a surprisingly strong factor in explaining individual microbiome differences,” said Dr. Oliver Aasmets, lead author.
The research team analyzed prescription data spanning five years before stool sample collection, creating an unprecedented timeline of medication exposure. They discovered that antidepressants, beta-blockers, proton pump inhibitors, and various other human-targeted drugs all left distinct microbial signatures that persisted long after treatment ended.
Even more intriguing, the effects appeared to be additive. People who had taken more prescriptions of a particular drug class showed greater microbiome alterations, suggesting that medication history operates on a dose-response relationship that accumulates over time.
Hidden Confounders in Medical Research
The implications extend far beyond individual health to the integrity of medical research itself. Current microbiome studies typically account only for medications taken at the time of sample collection, potentially missing a major source of variation that could confound disease associations.
To validate their cross-sectional findings, researchers analyzed follow-up samples from 328 participants collected after a median of 4.4 years. Despite the smaller sample size, they confirmed that starting or stopping medications like proton pump inhibitors, selective serotonin reuptake inhibitors, and various antibiotics produced predictable shifts in gut bacteria composition.
“This is a comprehensive systematic evaluation of long-term medication effects on the microbiome using real-world medical health records,” said Professor Elin Org, corresponding author. “We hope this encourages researchers and clinicians to factor in medication history when interpreting microbiome data.”
The study also revealed notable differences between medications within the same therapeutic class. Alprazolam and diazepam, both benzodiazepines used for anxiety, showed markedly different microbiome impacts, with alprazolam producing broader effects. Similarly, different beta-blockers and proton pump inhibitors varied considerably in their microbial footprints.
The research suggests that human-targeted medications may act similarly to antibiotics in some respects, potentially explaining why the microbiome diversity of former drug users never fully recovers to match that of people who have never taken these medications. This finding raises questions about whether commonly prescribed drugs might have unintended consequences for gut health that persist long after treatment ends.
For the 34% of study participants who weren’t taking any prescription drugs at the time of sampling, their medication-free status represented just a snapshot. Analysis of the five-year prescription history revealed that 507 different medications had been used by participants during that period, highlighting the complexity of real-world drug exposure patterns.
The Estonian study leveraged electronic health records to overcome limitations of self-reported medication data, which often suffers from underreporting. This approach allowed researchers to capture the full spectrum of prescription drug use in a population-based volunteer cohort, providing insights into medication effects in generally healthy individuals rather than disease-specific populations.
As the field of microbiome research continues to evolve, these findings suggest that understanding the bacterial communities in our gut requires looking not just at what we’re taking now, but at the pharmaceutical journey our microbes have experienced over years of our lives. The invisible pharmacy in our medicine cabinets may be writing prescriptions for our gut bacteria long after we’ve forgotten taking the pills.
mSystems: 10.1128/msystems.00541-25
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.